External Quality Assessment Scheme

Haemoglobin A1c Round 1, 2023

Specimens

Please find enclosed 2 commercial human blood samples, S003 and S004, each $0.5\ \mathrm{mL}.$

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations

HbA1c

Storage and use

We recommend analyzing the samples as soon as possible. If this is not possible, store in a refrigerator (+ 2... + 8 ° C). Do not freeze. The samples should be analysed in the same way as patient samples. Allow the tube to stand at room temperature for about 15 minutes. Mix the sample by inverting the tube several times, until the suspension appears homogeneous. Do not mix too vigorously. Do not use mechanical blood mixers. Samples will be usable for 2 months from the date of this letter.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator.

S003:



S004:



2023-02-06

INSTRUCTIONS

Product no. 1261 LQ729423013-014/US

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi

The results should be reported no later than **February 23, 2023**.

Inquiries

EQA Coordinator Päivi Ranta paivi.ranta@labquality.fi

Labquality Oy

Kumpulantie 15 FI-00520 HELSINKI Finland

Tel. + 358 9 8566 8200 Fax + 358 9 8566 8280

info@labquality.fi www.labquality.com





22/02

22/02

22/01

La21 53

La22 53

La21 53

56.5

40.6

59.6

60.0

41.0

56.0

6.2 1.6

1.0 0.2

-6.0 -0.9

-16

20

40

60

Conc./act. mmol/mol

Sample 003

HbA1c 2023/1

Sample 004 Page: 1(2) Roche Cobas Integra HbA1c Integra HbA1C 0199 53 (X_{pt}) (X_{pt}) 115.0 mmol/mo 25 mmol/mol mmol/mol 20 105.0 of res. No. of res. 15 0 95.0 10 Š 8 85.00 Sample 44 0 52.0 60.0 68.0 76.0 84 0 55.0 65.0 75.0 85.0 95.0 105.0 115.0 75.0 Own result Own result 85.0 -6.4% analysed: 15.2.2023 analysed: 15.2.2023 Sample 003 Sample 004 65.0 0 Assigned value (X): 60.5 mmol/mol, X_{pt} Assigned value (X): 90.8 mmol/mol, X_{pt} Target limits (X ± 8%): 55.7 - 65.3 mmol/mol Target limits (X ± 8%): 83.5 - 98.1 mmol/mol CV% CV% 55.0 n 60.48 90.78 44.0 52.0 60.0 68.0 76.0 84.0 4.21 2.11 7.0 4.15 2.08 4.6 4 58.24 3.41 5.9 89.21 3.85 0.73 4.3 44 0.64 ΑII Sample 003 Conc./act. dependent performance Previous results Comments Round Sample Own Sample 003, Own group: 16 The standard measurement uncertainty (u) of the assigned value (Xpt) is the standard error of the mean (SEM). 23/01 La25 53 60.5 -9.1 55.0 The uncertainty (u) of the mean and the assigned value (Xpt) is not negligible, and evaluations could be affected. When a reference method value is used as assigned value (Xref), its 23/01 La24 53 85.0 -6.4 90.8 22/06 La22 53 40.3 37.0 -8.2 uncertainty is mentioned in the report letter. Due to the small number of results, the z score is not calculated. 22/06 La23 53 58 4 57.0 -24 22/05 La22 53 40.0 34.0 -15.0 -1.5 mmol/mo Sample 004, Own group: n The standard measurement uncertainty (u) of the assigned value (Xpt) is the standard error of the mean (SEM). The uncertainty (u) of the mean and the assigned value (Xpt) is not negligible, and evaluations could be affected. When a reference method value is used as assigned value (Xref), its uncertainty is mentioned in the report letter. Due to the small number of results, the z score is not calculated. 22/05 La24 53 92.8 88.0 -5.2 -0.6 22/04 La21 53 57.8 56.0 -3.1 -0.7 Diff. 22/04 La24 53 90.0 91.0 1.1 0.2 -8 -8 22/03 La21 53 57.6 58.0 0.7 0.1 22/03 La19 53 83.5 85.0 1.8 0.3

-16

100

80

Laboratory: XXXX

Powered by Innovatics 27.2.2023 © Labquality 2023

LABQUALITY Sample 003 HbA1c 2023/1 Laboratory: XXXX Page: 2(2)

Participants	
101 participants from 15 countries.	
Report info	
Your own result should be compared to the given target value which can be reference method value (Xref) or the mean of the own method group (value, its uncertainty and measurement method given in the report letter.	Xpt or Xrob). The reference method
The assigned values are calculated according to the robust procedure described in the standard ISO 13528 (Statistical methods for use in proficie comparisons, Annex C, Algorithm A). The standard uncertainty of the assigned value is expressed as 1.25 x the standard error of mean (SEM) and Due to its iterative mode algorithm A adds the uncertainty of the assigned value and with this factor we want to adjust uncertainty accordingly. Plea only 1 result only the client's own result is shown. No target value (except for reference method values or transferred values) is calculated, no targe 12 results in a method group, the robust calculation is not used but a calculation where results deviating more than +/- 3*standard deviation SD from the measurement uncertainty of the target value is too large ((u(xpt) < 0.1dE)) an automatic text is printed on the report: "The uncertainty of the availuations could be affected." In case there are 2-5 results in a method group, no z-score is calculated, and a text is printed on the report: "Due to is not calculated." In case there are 6-12 results, the report has a text: "Z score is uncertain due to the small number of observations."	d marked as "u" in numerical summary. ase notice also that for groups that have et areas are shown. In case there are 2- om the median are removed. Additionally, assigned value is not negligible, and
Results reported with < tai > -signs cannot be included in the statistics.	
For information on report interpretation and performance evaluation, please see the " EQAS Interpretation guidelines" in LabScala User instruction	s.

Powered by Innovatics 27.2.2023 © Labquality 2023

NUMERICAL SUMMARY

HbA1c 2023/01

Analyte	Method group	х	med	s	CV%	u	Min	Max	Number
Sample	001								
HbA1c, m	nmol/mol								
Abbott	Alinity	51.43	51.5	0.39	8.0	0.23	51.0	51.8	3
	Architect enzymatic	50.58	50.8	0.53		0.30	50.0	51.0	3
	Bio-Rad D-10	53.00 52.46	53.0	0.00		0.00	53.0	53.0	2
	HPLC Tosoh		52.5	0.98	1.9	0.21	50.8	54.3	34
	Roche cobas c Tina-quant		53.0	1.05 1.41	2.0	0.38	33.3	54.0 52.0	12
	Sebia Capillary electrophoresis		51.0 57.1	1.41	2.8	1.00	50.0	52.0	1
	Siemens Advia Analysers Siemens Advia Centaur & Atellica		51.5	1.20		0.43	- 49.1	53.3	8
	ns DCA 2000+ & Vantage	51.43 51.75	51.0	2.76	5.3	0.87	47.0	56.0	10
	Scientific Konelab	50.77	51.0	2.02		0.61	48.0	54.0	11
All		52.04	52.0	1.39	2.7	0.15	33.3	57.1	86
Sample	002								
HbA1c, m									
Abbott		31.72	31.9	0.64	2.0	0.37	31.0	32.2	3
Abbott	Architect enzymatic	32.30	32.1	0.43	1.3	0.25	32.0	32.8	3
HPLC E	Bio-Rad D-10	32.50	32.5	0.71	2.2	0.50	32.0	33.0	2
HPLC 1	Tosoh	34.33	34.3	0.89	2.6	0.19	31.9	36.6	34
	cobas c Tina-quant	33.93	34.0	1.36	4.0	0.49	32.0	53.0	12
	Capillary electrophoresis	34.00	34.0	0.00	0.0	0.00	34.0	34.0	2
	ns Advia Analysers	38.02	38.0	-	-	-	-	-	1
	ns Advia Centaur & Atellica	32.24	32.5	1.23		0.43	30.0	33.8	8
	ns DCA 2000+ & Vantage o Scientific Konelab	34.25	34.0	1.51	4.4	0.48	32.0	37.5 42.0	10 11
	o Scientific Konerad	35.33	34.7	2.98	8.4	0.90	31.0		
All		33.93	34.0	1.45	4.3	0.16	30.0	53.0	86
Sample									
HbA1c, m									
Abbott	•	57.79	57.8	0.28	0.5	0.20	57.6	58.0	2
	Architect enzymatic	60.75	59.1	3.87	6.4	1.73	57.0	67.0	5
-	Adams A1c	55.20 56.20	55.2 57.0	2.06	-	-	- -	- -	1
	an Coulter an Coulter AU instruments	56.20 53.15	57.0 52.5	3.86 1.62		2.23 0.93	52.0 52.0	59.6 55.0	3 3
	Bio-Rad D-10	51.90	51.9	1.56	3.0	1.10	50.8	53.0	2
HPLC 1		61.20	61.2	0.85		0.60	60.6	61.8	2
	entation laboratory	78.90	78.9	-	-	-	-	-	
	b & Quo-Test HbA1c	63.04	63.0	1.21	1.9	0.86	62.2	63.9	2
Roche	cobas c Tina-quant	58.55	58.0	1.04	1.8	0.36	54.1	60.0	13
Roche	Cobas Integra	60.48	61.2	4.21	7.0	2.11	55.0	64.5	4
Siemer	ns Advia Centaur & ACS	58.00	58.0	-	-	-	-	-	1
	ns Advia Centaur & Atellica	56.07	55.6	1.16	2.1	0.67	55.2	57.4	3
	ns Dimension & Vista	60.00	60.0	-	-	-	-	-	1
	Scientific Konelab	58.00	58.0	-	-	-	-	-	1
All		58.24	58.0	3.41	5.9	0.51	50.8	78.9	44
Sample									
HbA1c, m		20	20.0	0.05		0.00			_
Abbott	•	88.63	88.6	0.95		0.68	88.0	89.3	2
	Architect enzymatic	93.20	92.0 83.6	4.30		1.92	89.0	100.2	5
-	Adams A1c an Coulter	83.60 86.77	83.6 88.0	- 5.26		3.04	- 81.0	91.3	1 3
	an Coulter AU instruments	85.26	85.0	0.46		0.26	85.0	91.3 85.8	3
	Bio-Rad D-10	84.15	84.2	3.89		2.75	81.4	86.9	2
HPLC 1		91.15	91.2	0.21	0.2	0.15	91.0	91.3	2
									_

NUMERICAL SUMMARY HbA1c 2023/01, Sample 004

Analyte	Method group	x	med	s	CV%	u	Min	Max	Number
HbA1	c, mmol/mol								
Instrumentation laboratory		64.20	64.2	-	-	-	-	-	1
Quo-La	b & Quo-Test HbA1c	95.71	95.7	7.62	8.0	5.39	90.3	101.1	2
Roche o	cobas c Tina-quant	90.30	90.0	2.54	2.8	0.88	88.0	96.4	13
Roche (Cobas Integra	90.78	91.6	4.15	4.6	2.08	85.0	94.9	4
Siemen	s Advia Centaur & ACS	85.00	85.0	-	-	-	-	-	1
Siemen	s Advia Centaur & Atellica	87.69	86.9	2.19	2.5	1.26	86.0	90.2	3
Siemen	s Dimension & Vista	90.00	90.0	-	-	-	-	-	1
Thermo	Scientific Konelab	87.00	87.0	-	-	-	-	-	1
All		89.21	89.2	3.85	4.3	0.58	64.2	101.1	44

Participants

101 participants from 15 countries.

Report info

Your own result should be compared to the given target value which can be reference method value (Xref) or the mean of the own method group (Xpt or Xrob). The reference method value, its uncertainty and measurement method given in the report letter.

The assigned values are calculated according to the robust procedure described in the standard ISO 13528 (Statistical methods for use in proficiency testing by interlaboratory comparisons, Annex C, Algorithm A). The standard uncertainty of the assigned value is expressed as $1.25 \, x$ the standard error of mean (SEM) and marked as "u" in numerical summary. Due to its iterative mode algorithm A adds the uncertainty of the assigned value and with this factor we want to adjust uncertainty accordingly. Please notice also that for groups that have only 1 result only the client's own result is shown. No target value (except for reference method values or transferred values) is calculated, no target areas are shown. In case there are 2-12 results in a method group, the robust calculation is not used but a calculation where results deviating more than +/- 3*standard deviation SD from the median are removed. Additionally, if the measurement uncertainty of the target value is too large ((u(xpt) < 0.1dE)) an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected." In case there are 2-5 results in a method group, no z-score is calculated, and a text is printed on the report: "Due to the small number of results, the z score is not calculated." In case there are 6-12 results, the report has a text: "Z score is uncertain due to the small number of observations."

Results reported with < tai > -signs cannot be included in the statistics.

For information on report interpretation and performance evaluation, please see the " EQAS Interpretation guidelines" in LabScala User instructions.

External Quality Assessment Scheme

Haemoglobin A1c, liquid samples Round 1, 2023

Specimens

Sample S003 (LQ729423013) and sample S004 (LQ729423014) were human blood samples.

Based on the previous tests and the results of this round, the samples are homogeneous, stable and suitable for the external quality assessment scheme.

The materials were sent without temperature control packaging.

Report info

Please see the description of the data analysis on the last page of the laboratory-specific histogram and Global report. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments - EQA coordinator

The level of sample S003 was elevated and level of sample S004 was high. The mean of all results was 58.24 mmol/mol for sample S003 and 89.21 mmol/mol for sample S004.

If any extra peaks are found, they may be caused by the denatured hemoglobin which may occur in chromatographic methods. But in these findings may reveal many system errors shown only in chromatographic runs.

Comments – Expert

HbA1c round 1/2023 both samples S003 and S004 were higher than the diagnostic limit of ADA (48 mmol/mol). The mean (all results) of HbA1c samples S003 and S004 were 58.24 and 89.21 mmol/mol, respectively. None of method groups differed significantly from the mean values. The total variation was 5.9% for the sample S003 and 4.3% for the sample S004. The CV%s of the samples were low and better than in the previous round.

End of report

2023-03-14

FINAL REPORT

Product no. 1261

 Samples sent
 2023-02-06

 Round closed
 2023-02-23

 Final report
 2023-03-14

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator Päivi Ranta paivi.ranta@labquality.fi

Expert

PhD, clinical chemist, Niina Tohmola, HUSLAB, Helsinki, Finland

Labquality Oy

Kumpulantie 15 FI-00520 HELSINKI Finland

Tel. + 358 9 8566 8200 Fax + 358 9 8566 8280

info@labquality.fi www.labquality.com





Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.